Anticancer compositions
OwnerAkikuni Yagitainventor
Life of this patent
Estimating the term…
Abstract
There is provided a composition or a composition for oral administration which contains a mycelium fraction of a product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient and induces the production of interleukin 12 (IL-12) or a supplementary food preparation for health by oral administration which is taken with an expectation of anticancer effect. There are also provided a commercial medium carrying the information concerning the above and a commercial method using the said commercial medium.
Claims23
A composition which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient.
A composition which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that, as the dose achieving the inducing ability for the production of IL-12 in vivo, the main ingredient is administered per os in a dose of 100 mg to 2,000 mg/kg body weight/day.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that, as the dose achieving the inducing ability for the production of IL-12 in vivo, the main ingredient is administered per os in a dose of 100 mg to 2,000 mg/kg body weight/day.
A composition which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for the patient suffering from progress cancer or terminal cancer.
A composition which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for the patient suffering from progress cancer or terminal cancer.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for the patient suffering from progress cancer or terminal cancer.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for the patient suffering from progress cancer or terminal cancer.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient and is effective to patients suffering from progressive cancer or terminal cancer which is characterized in that, as the dose achieving the inducing ability for the production of IL-12 in vivo, the main ingredient is administered per os in a dose of 100 mg to 2,000 mg/kg body weight/day.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient and is effective to patients suffering from progressive cancer or terminal cancer which is characterized in that, as the dose achieving the inducing ability for the production of IL-12 in vivo, the main ingredient is administered per os in a dose of 100 mg to 2,000 mg/kg body weight/day.
A composition which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for patients suffering from cancer where a T helper 2 cell system immune response is mainly functioning.
A composition which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for patients suffering from cancer where a T helper 2 cell system immune response is mainly functioning.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for patients where a T helper 2 cell system immune response is mainly functioning.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient which is characterized in that it is useful for patients where a T helper 2 cell system immune response is mainly functioning.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by incubation of mycelia of Ganoderma boninense as a main ingredient and is effective to patients suffering from cancer where a T helper 2 cell system immune response is mainly functioning which is characterized in that, as the dose achieving the inducing ability for the production of IL-12 in vivo, the main ingredient is administered per os in a dose of 100 mg to 2,000 mg/kg body weight/day.
A composition for oral administration which induces the production of interleukin 12 (IL-12) containing a mycelium fraction of the product obtained by liquid incubation of mycelia of Ganoderma boninense as a main ingredient and is effective to patients suffering from cancer where a T helper 2 cell system immune response is mainly functioning which is characterized in that, as the dose achieving the inducing ability for the production of IL-12 in vivo, the main ingredient is administered per os in a dose of 100 mg to 2,000 mg/kg body weight/day.
Dependencies are inferred from the claim text.